31 results
424B3
CHRS
Coherus Biosciences Inc
26 Jul 23
Prospectus supplement
4:59pm
received equity investments of $13.5 million from Novartis.
Executive Officer and Director Compensation
See the section entitled “Executive … Compensation,” incorporated by reference to Surface’s Amendment No. 1 to its Annual Report on Form 10-K/A for the fiscal year ended December 31, 2022, filed
S-4/A
CHRS
Coherus Biosciences Inc
24 Jul 23
Registration of securities issued in business combination transactions (amended)
4:42pm
Compensation
See the section entitled “Executive Compensation,” incorporated by reference to Surface’s Amendment No. 1 to its Annual Report on Form 10-K
S-4
ovlhs5u7o by8
7 Jul 23
Registration of securities issued in business combination transactions
5:03pm